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Abstract
Introduction and Objectives Despite the recognized clini-
cal benefit of statins on cardiovascular prevention, pro-
viding correct management of hypercholesterolaemia,
possible adverse effects of their use cannot be disregarded.
Previously published data shows that there is a risk of
developing diabetes mellitus or experiencing changes in
glucose metabolism in statin-treated patients. The possible
determining factors are the drug characteristics (potency,
dose), patient characteristics (kidney function, age,
cardiovascular risk and polypharmacy because of multiple
disorders) and the pre-diabetic state.
Methods In order to ascertain the opinion of the experts
(primary care physicians and other specialists with
experience in the management of this type of patient) we
conducted a Delphi study to evaluate the consensus
rate on diverse aspects related to the diabetogenicity of
different statins, and the factors that influence their
choice.
Results Consensus was highly significant concerning
aspects such as the varying diabetogenicity profiles of
different statins, as some of them do not significantly
worsen glucose metabolism. There was an almost unani-
mous consensus that pitavastatin is the safest statin in this
regard.
Conclusions Factors to consider in the choice of a statin
regarding its diabetogenicity are the dose and patient-re-
lated factors: age, cardiovascular risk, diabetes risk and
baseline metabolic parameters (which must be monitored
during the treatment), as well as kidney function.
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Consensus
Key Points
To minimize the risk of metabolic changes related to
prediabetes or diabetes it is important to select the statin
treatment in accordance with the patients and drugs
characteristics
All statins do not exert a similar influence on glucose
metabolism
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1 Introduction
The introduction of HMG-CoA reductase inhibitors in the
treatment of dyslipidaemia, specially statins as cholesterol-
lowering drugs, has been one of the biggest milestones in
the recent history of cardiovascular events prevention, and
there are numerous interventional studies that have
demonstrated their clinical benefits in different scenarios of
cardiovascular prevention [1, 2].
In patients with diabetes, the benefit of statins is also
significant, and can be greater than that found in high-risk
non-diabetic patients [3]. The 4S, CARE, LIPID, and HPS
studies have demonstrated decreased cardiovascular
events and total mortality in patients with Type 2 Dia-
betes Mellitus (DM2) treated with statins [4–7]. In the
analysis of diabetic patients in the ASCOT-LLA study
[8], a reduced risk of cardiovascular accidents was also
observed with atorvastatin, though it was not significant.
However, in another study in diabetics (CARDS) [9], it
was possible to demonstrate a clear and significant
reduction in cardiovascular accidents with atorvastatin,
even in patients with low levels of low-density lipoprotein
cholesterol (LDL-C).
However, treatment with statins is not devoid of pos-
sible unwanted side effects [10]. These effects usually
depend on different factors such as the type and dose of
the statin used the patient’s characteristics (age, kidney
function, etc.) and the possible interactions with other
drugs in patients who, due to multiple illnesses or
comorbidity, are prescribed multiple medications. One of
the adverse effects described has been the effect on glu-
cose metabolism, modifying the levels of fasting glucose
and glycosylated haemoglobin, and an increase in the
onset of new cases of diabetes [11, 12]. Despite these
effects, and as a result of the beneficial effect of statins in
cardiovascular medicine, the European Medicines Agency
(EMA) acknowledged the superiority of the potential
benefits against the possible onset of new cases of dia-
betes [13]. However, the diabetogenic effect of statins
may have been underestimated thus far, as most data has
been collected from short-term clinical trials of up to 5
years [14], whereas the risk of onset of diabetes can
remain increased for at least 20 years since the start of
treatment [15].
The evidence collected from different meta-analyses
indicates that statins may increase the risk of type 2 dia-
betes mellitus [16, 17]. The most significant meta-analysis
[17] has indicated that statin therapy is associated with a
9% increase in the risk of new cases of type 2 diabetes
mellitus over 4 years, and that this risk is higher in older
patients. However, this percentage can be increased in a
striking way. In a study [18] involving 17,802 subjects
treated with rosuvastatin in primary prevention, it was
observed that the absolute risk of type 2 diabetes mellitus
could be increased by up to 28 % after 5 years of treat-
ment; especially in patients with pre-diabetes: subjects with
metabolic syndrome, impaired fasting glucose, obesity
(BMI C30 kg/m2), or with glycosylated haemoglobin
(HbA1c)[6 %. In a review of more than 15,000 patients
[19], it was shown that the components of the metabolic
syndrome were predictors of the onset of type 2 diabetes
mellitus in statin-treated patients.
With regard to specific conditions of statins, a meta-
analysis of five clinical trials involving about 33,000 non-
diabetic patients showed that intensive treatment with high
doses of statins may increase the risk of new cases of
diabetes by 12 % as compared to low doses [20]. Recent
data from a retrospective study of actual clinical practice
with more than 470,000 non-diabetic patients over 66 years
of age treated with statins over a period of 14 years also
showed a diabetogenic effect of statins associated with
high (atorvastatin and rosuvastatin) or moderate (simvas-
tatin) potency statins, with a 22 and 11 % higher risk of
onset of new diabetes, respectively [21]. Another popula-
tion study, involving about 137,000 patients older than
40 years of age, confirmed that the risk of developing type
2 diabetes mellitus is 15 % higher with high potency statins
than low potency statins since 2 years after the start of
treatment [22].
Summarizing, it is necessary to include diabetogenicity
as one of the considerations in clinical practice when pre-
scribing a treatment with statins. It appears to be a class
effect although there may be differences based on the type
of statin, the dose, its potency, as well as the patient profile
(pre-diabetic condition or older age). Thus, in order to
achieve the improvement in cardiovascular risk
attributable to the statin, without increasing the risk of
inducing alterations in glucose metabolism or generating
diabetes, we should select the most favourable statin
according to the patient profile.
This study has been proposed in order to ascertain the
degree of consensus among physicians with wide experi-
ence in the management of patients requiring treatment
with statins, about the factors that contribute to drug
selection when there is impaired glucose metabolism. In
particular, the objectives were to receive feedback on
whether all statins have a similar or different diabetogenic
effect and to establish recommendations on the statin
selection based on the patient characteristics. The results
shown are part of the DIANA study (DelphI study: multi-
disciplinary consensus on the stAtiN of choice in patients
with Altered glucose metabolism).
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2 Methods
2.1 Study Design
The modified Delphi method [23] was used to reach the
greatest consensus possible from a broad panel of dyslip-
idaemia experts. It is a structured technique for remote
consensus, a variant of the original procedure developed by
Dalkey et al. at Rand Corporation Santa Monica (Cali-
fornia, United States) [24, 25], which maintains its key
advantages (controlled interaction, opportunity to recon-
sider an opinion and statistical validation of consensus)
over other technical alternatives and it addresses some of
their major drawbacks (opinion biases) [26].
Its execution required two successive waves of a struc-
tured survey filled out through an online platform. The
doctors were able to confidentially compare their personal
opinions with the overall opinion of the panel when
answering the second wave and could reconsider, where
appropriate, their initial criteria on issues where there was
no consensus.
The study was conducted in four phases: (a) the selec-
tion of a scientific committee, responsible for the formu-
lation of the survey questions; (b) the selection of an expert
panel of professionals from four specialties (cardiology,
endocrinology, internal medicine, nephrology) and family
and community medicine with experience in the field of
dyslipidaemia; (c) an online survey in two waves; and
(d) an analysis of results and discussion of conclusions in a
meeting held by the scientific committee.
The project was performed over 5 months between
February and June 2015 (wave 1 and wave 2, successively),
using the email as the distribution channel.
2.2 Preparation of the Questionnaire
The project’s scientific committee revised the contents of
the Delphi questionnaire. A bibliographic search prioritis-
ing systematic reviews was conducted as well as another
critical synthesis of scientific literature through the con-
sultation of bibliographic databases (MEDLINE, EMBASE
and the Spanish Medical Index) [27], and a manual review
of the references obtained to find other references that may
be of interest by using keywords such as dyslipidaemia,
diabetogenicity or impaired glucose metabolism.
Each survey question submitted to the panel for
assessment was devised in the form of a positive or neg-
ative statement, as a clinical recommendation responding
to interesting or controversial aspects in the clinical man-
agement of patients with dyslipidaemia and impaired glu-
cose metabolism. The final version of the questionnaire,
included in this article, contained 2 blocks of questions: (1)
Opinion on the profile of statins in the treatment of
dyslipidaemia in patients with impaired glucose metabo-
lism (16 questions), and (2) Recommendations for the
selection of the lipid-lowering treatment of choice in
patients with impaired glucose metabolism (24 questions).
2.3 Selection of a Panel of Experts
The experts proposed were selected by the committee
based on their medical and scientific expertise and con-
sidering their interest in dyslipidaemia. For their recruit-
ment, a ‘‘snowball’’ strategy was used from personal
contacts of the committee members, who in turn proposed
new candidates from their professional environment [28].
Following this process, 506 professionals were invited, of
which 497 experts from all autonomous communities in
Spain agreed to participate. All of them were practitioner
clinical doctors: 58.4 % primary care physicians; 13.7 %
endocrinologists; 13.9 % internal medicine; 7.0 % cardi-
ologists; and 7.0 % nephrologists.
2.4 Analysis and Interpretation of Results
A single type of rating scale was proposed for all questions,
an ordinal Likert scale of nine points, from 1: total dis-
agreement (strongly disagree/never/not important/not nec-
essary/not at all appropriate) to 9: total agreement (strongly
agree/always/very important/absolutely necessary/totally
appropriate), according to the format developed at UCLA-
Rand Corporation for the evaluation method of the
appropriate use of medical technology [27]. The categories
were divided into three regions (1–3: Disagree; 4–6:
Neutral; 7–9: Agree), systematising the submission of
responses as shown in Fig. 1.
All questions had to be answered in wave 1. In wave 2,
the questions for which consensus was not achieved in
wave 1 were asked again.
Consensus was deemed to be reached when a question
obtained at least 80 % of responses grouped in scores 1–3
(consensus in disagreement) or scores 7–9 (consensus in
agreement).
Data were analysed globally and according to the by
specialty of the participating doctors. The comparative
analysis by specialty was conducted using the Chi-square
or Fisher statistical tests. To conduct the comparative
analysis between waves, Bowker’s test was used, an
adaptation of McNemar’s test to compare variables from
Fig. 1 Scoring scale and levels of agreement and disagreement
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more than 2 categories. In both cases the established level
of statistical significance was 0.05 bilateral.
3 Results
The first results refer to the degree of agreement or
consensus among the experts consulted about the dia-
betogenic effect of different statins, in the case that a
patient with impaired glucose metabolism requires treat-
ment with a statin. The consensus percentages reached
(greater than 80 % between respondents was considered
relevant) are summarized in Table 1 and Fig. 2. Further-
more, the existing differences are shown, where applica-
ble, between primary care physicians and those from
other specialties.
The experts primarily agreed that the diabetogenic
profile varies among statins. In addition, 78.9 % of the
specialists practically unanimously disagree with the
statement that pitavastatin impairs glucose metabolism or
increases the risk of onset of diabetes, being considered the
safest statin in this respect.
However, there are many aspects for which agreement
or a significant consensus was not reached. For example,
consistent with the above, only 10.7 % of the physicians
believe that all statins can alter glucose metabolism.
However, there are other aspects for which a greater degree
of consensus was expected, for example, ‘‘the more potent
statins and statins at higher doses may impair glucose
metabolism or glycaemic control’’. Although most of the
experts consider that atorvastatin, simvastatin and rosu-
vastatin have the greatest effect, less than 80 % (considered
significant) of them agree with this statement. It should be
noted that primary care physicians believe that the most
potent statins can impair glucose metabolism or impair its
control in diabetics in a significantly higher percentage
than other specialists.
The results of the second objective, concerning selection
criteria of a statin in patients with abnormal glucose
metabolism, and what can be considered the statin of
choice are shown in Table 2 and Fig. 3. The degree of
consensus in these aspects is very high. Thus, it should be
noted that the recommendations for selecting a particular
statin for a patient with abnormal glucose metabolism or
overt diabetes mellitus are: (a) to assess the cardiovascular
risk and risk of diabetes mellitus; (b) to assess the patient
profile, including age, polypharmacy, kidney function and
albuminuria, and levels of fasting plasma glucose and
HbA1c; and (c) to select a statin that has demonstrated a
neutral or beneficial effect. Regarding the statin considered
the safest in the opinion of the experts consulted, the
majority considers that pitavastatin is the best choice for
pre-diabetic and diabetic patients (Fig. 3). It is the only
statin that reaches such a consensus, being the proportion
of doctors from the specialities higher (significant) in
comparison with primary care physicians.
4 Discussion
The diabetogenicity of statins appears to be associated with
the statin itself: higher lipid-lowering potency, higher doses
and longer treatment duration are predisposing conditions.
Patient-specific factors, such as older age, impaired kidney
function, cardiovascular risk and multiple illnesses or
comorbidity, which usually includes polypharmacy [29],
are also key factors. Furthermore, situations considered
pre-diabetic are also predisposing factors, such as patients
with metabolic syndrome, visceral obesity, impaired fast-
ing glucose or intolerance to oral glucose load [18, 19].
With regard to the potential different effect of the dif-
ferent statins, several studies have shown such differences.
We found that 83.3 % of doctors agree that statins have
differences in their diabetogenic effect, while 78.7 % of
Table 1 Degree of consensus on issues concerning the effect of statins on glucose metabolism (significant agreements and differences are
indicated)
Issue(1) Degree of consensus %
(95 % CI)(2)
p (PC vs OS)(3)
The diabetogenic profile of statins differs among them 83.3 (80.0-86.6) 0.0603 (82.1 vs 85.0)
There are statins that do not impair glucose metabolism 78.7 (75.1-82.3) 0.3668 (77.2 vs 80.7)
The diabetogenic effect of statins is proven 54.3 (49.9-58.7) 0.1831 (52.1 vs 57.5)
The most potent statins may alter glucose metabolism 52.5 (48.1-56.9) <0.0001 (44.8 vs 66.3)
The most potent statins may impair glycaemic control in patients with diabetes mellitus 43.3 (38.9-47.7) <0.0001 (39.7 vs 48.3)
All statins at high doses may alter glucose metabolism in patients with pre-diabetes 20.7 (17.1-24.3) 0.9369 (21.0 vs 20.3)
All statins at high doses may impair glycaemic control in patients with pre-diabetes 20.5 (17.0-24.0) 0.6215 (21.4 vs 19.3)
All statins alter glucose metabolism 10.7 (8.0-13.4) 0.2468 (12.4 vs 8.2)
(1) Item for which the expert’s opinion is requested (2) 95% CI: 95% Confidence Interval. Consensus percentage[7 on the Likert scale. Bold
values refer to an agreement above 80%. (3) PC: Primary Care; OS: Other Specialties. Bold values refer statistical significance
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doctors also thought that some statins do not impair glu-
cose metabolism, and 78.9 % profoundly disagreed that
pitavastatin modifies glucose metabolism. However, high
doses of statins have not been identified as a key element.
As a consequence, our results lead us to suspect a certain
lack of awareness of the diabetogenic profile of the dif-
ferent statins, supported by the doubts expressed about the
evidence and extent of the diabetogenic effect based on the
potency of the statin, both in subjects with and without
diabetes mellitus. It is worth highlighting that no differ-
ences were seen in the answers given by primary care
physicians and those of other specialities.
There was consensus that pitavastatin is the best choice
both in pre-diabetic patients (91.1 % consensus) and in
patients who have already been diagnosed of diabetes
(92.2 % consensus); while the other statins are either not
considered to be a suitable choice or their suitability is
unknown. There is a small but significant difference
between the consensus percentages concerning the choice
of pitavastatin in pre-diabetic patients when primary care
physicians (91.8 % consensus) are compared to other
specialists (90.7 % consensus). This is consistent with the
recent publication of the first meta-analysis focusing on the
individualised effects of pitavastatin [30], which has
Fig. 2 Degree of consensus on
the evaluation of the
diabetogenic effect of
cholesterol-lowering drugs
(Consensus percentage C7 on
the Likert scale. It is considered
significant if it is above 80%).
(*) Primary care vs Other
specialties
Table 2 Degree of consensus on recommendations to choose a statin considering its possible effect on glucose metabolism (significant
agreements and differences are indicated)
Issue(1) Degree of consensus %
(95 % CI)(2)
p (PC vs OS)(3)
The cardiovascular risk must be evaluated when prescribing a statin 94.8 (92.8-96.8) 0.4433 (94.1 vs 95.7)
It is useful to evaluate the patient’s multiple medications when prescribing a statin 89.5 (86.8-92.2) 0.5668 (90.7 vs 87.9)
It is useful to consider the patient’s renal function / albuminuria when prescribing a statin 86.5 (83.5-89.5) 0.4652 (87.0 vs 93.1)
For a patient with altered glucose metabolism, a statin that has demonstrated that it does not
impair this metabolism should be selected.
85.7 (82.6-88.8) 0.0845 (88.6 vs 81.6)
For a diabetic patient, a statin that has demonstrated that it does not impair glucose
metabolism should be selected.
84.7 (81.5-87.9) 0.0003 (90.0 vs 77.3)
In the follow-up of patients in treatment with statins, glucose levels should be regularly
monitored.
84.7 (81.5-87.9) 0.0795 (83.1 vs 87.0)
It is useful to evaluate the patient’s age when prescribing a statin 82.9 (79.6-86.2) 0.2053 (83.8 vs 81.6)
It is useful to consider the patient’s fasting plasma glucose when prescribing a statin 81.5 (78.1-84.9) 0.5370 (80.3 vs 83.1)
The risk of diabetes mellitus should be determined when prescribing a statin 81.3 (77.9-84.7) 0.0150 (85.2 vs 75.8)
It is useful to consider the patient’s HbA1c levels when prescribing a statin 80.3 (76.8-83.8) 0.0682 (77.2 vs 84.5)
(1) Item for which the expert’s opinion is requested. (2) 95% CI: 95% Confidence Interval. Consensus percentage[7 on the Likert scale. Bold
values refer to an agreement above 80%. (3) PC: Primary Care; OS: Other Specialties. Bold values refer statistical significance
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revealed that, relative to the controls (placebo and other
statins), in subjects without prior diabetes the incidence of
diabetes or deterioration of glucose metabolic control
(fasting plasma glucose and/or HbA1c) is not increased.
This evidence is in line with data collected in patients with
impaired glucose tolerance, in these patients, pitavastatin
showed a neutral effect and even some protection to the
onset of diabetes [31, 32]. Summarizing, pitavastatin is
perceived as the best choice, both in diabetic [29] and in
pre-diabetic [33] patients.
It seems interesting to note the level of consensus con-
cerning other recommendations when prescribing a statin.
There is consensus on assessing the cardiovascular risk
(94.8 % of experts), the patient’s polypharmacy (89.5 %)
and taking into account kidney function and the presence of
albuminuria (86.5 %). Likewise, 82.9 % agree on the
importance of considering the patient’s age. It is important
to mention that doctors agreed that, before prescribing a
statin, it is necessary to assess the risk of developing dia-
betes (81.3 % of responders), and it is necessary to select a
statin that has demonstrated that it does not impair the
glycaemic profile, both in diabetic patients (84.7 %) and in
those with impaired glucose metabolism (85.7 %), also, it
is necessary to assess the levels of fasting plasma glucose
(84.7 %) or the HbA1c levels (80.3 %).
It should be noted that primary care physicians seemed
generally more concerned about the possible diabetogenic
effect of statins than other specialists. They showed greater
consensus on the need to monitor that the statin does not
impair glycaemic control in diabetic patients (90 vs
77.3 %), and calculate the risk of developing diabetes
mellitus prior to the use of a statin (85.2 vs 75.8 %). This
latter recommendation from our experts is aligned with the
latest recommendations from experts who support
assessing the risk of developing DM2 in patients who start
a treatment with statins [34]. The European Atherosclerosis
Society has established some recommendations to evaluate
the risk of diabetes at 10 years using a validated instrument
(FINDRISC), and to assess and periodically monitor the
levels of fasting plasma glucose and HbA1c. This is in line
with the opinion and consensus given in our study as
evaluating the risk at 10 years and periodically assess the
levels of plasma glucose and HbA1c is the recommenda-
tion that achieves the greatest degree of consensus among
the experts consulted [34].
The selection of the statin (drug and doses) to treat high
risk patients is a critical decision. Clinical benefits of
pitavastatin, with focus on patients with diabetes or at risk
of developing diabetes was recently published [35].
According to drug evaluation, pitavastatin is a moderate- to
high-intensity statin that effectively reduces LDL choles-
terol levels. In addition, provides a neutral or positive
effect on glucose metabolism and does not increase the risk
of new-onset diabetes. Therefore, it seems that pitavastatin
should preferentially be considered in the treatment of
dyslipidaemia in diabetic patients or at risk of developing
diabetes. Several mechanism have been proposed to
explain the association of statins and new-onset diabetes:
calcium channel blockage in beta cells, decreased glucose
transporter 4 (GLUT4) expression, diminished levels of
coenzyme Q10, and cholesterol uptake in pancreatic beta
cells [36]. These biomolecular mechanisims are the most
relevant to explain the divergences but we have limited
high-quality evidences to confirm the mechanism behind
the different agents.
We need additional and well-designed studies to eluci-
date possible causes and comprehensive studies will
determine potential differences among individual statins.
Fig. 3 Degree of consensus on
the statin of choice in patients
with pre-diabetes or overt
diabetes (Consensus percentage
C7 on the Likert scale. It is
considered significant if it is
above 80%). (*) p Primary care
vs Other specialties
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The present consensus was highly significant concerning
aspects such us the varying diabetogenicity of different
statins, as some of them do not significantly worsen glu-
cose metabolism. Nonetheless, more studies are needed to
better understand this association as ours is only a posi-
tional study of the physician’s opinion. Our study could be
a contribution for a future clinical guide to support clinical
decisions.
5 Conclusions
Finally, it should be noted that, regardless of their
cholesterol-lowering power, statins should be selected
based on other effects, including: (1) their effect on
decreased triglycerides and increased HDL (residual vas-
cular risk); (2) patient characteristics: age, calculated car-
diovascular risk, multiple illnesses/comorbidity, multiple
medications and risk of interactions, kidney function; and
(3) underlying impaired glucose metabolism and potential
diabetogenicity, that show differences between certain
agents.
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